婦人科治療薬の世界市場

婦人科治療薬の世界市場は2030年までに81億米ドルに達する見込み

2024年に60億米ドルと推定される婦人科治療薬の世界市場は、分析期間2024-2030年にCAGR 5.3％で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである非ホルモン療法は、CAGR 4.1％を記録し、分析期間終了時には48億米ドルに達すると予測されます。ホルモン療法分野の成長率は、分析期間のCAGRで7.2％と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 8.2％で成長予測

米国の婦人科治療薬市場は2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.2%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の「婦人科治療薬」市場- 主要動向と促進要因のまとめ

婦人科治療薬が女性の健康管理の中心になりつつある理由とは？

婦人科治療薬は、月経障害、ホルモンバランスの乱れ、子宮内膜症から不妊症、更年期症状、婦人科感染症に至るまで、女性の生殖の健康に特有の幅広い症状に対応し、ヘルスケアの基本となっています。女性の健康問題を取り巻く意識が世界的に高まり続ける中、以前は汚名を着せられたり、治療が不十分であったりした問題に対して、積極的に医療介入を求める患者が増えています。このような文化的な変化は、ヘルスケアへのアクセスの増加とともに、的を絞った医薬品ソリューションへの需要を促進しています。婦人科に特化したクリニックの拡大や、プライマリ・ケアへの女性の健康の統合は、年齢層や地域を問わず、より早い診断とより一貫した治療に貢献しています。

イノベーションは婦人科疾患の治療選択肢をどのように再構築しているか？

婦人科治療薬市場は、より効果的で忍容性が高く、個別化された治療法の開発により急速に発展しています。ホルモン補充療法（HRT）、選択的エストロゲン受容体モジュレーター（SERM）、経口避妊薬は、安全性プロファイルを改善し、徐放性錠剤、膣リング、注射剤など、利便性を重視した投与方法に改良されています。更年期障害や子宮内膜症などの症状に対する非ホルモン薬は、副作用の懸念から代替薬を求める女性の間で人気を集めています。一方、婦人科がんや慢性骨盤炎症性疾患に対しては、標的生物製剤や免疫療法が検討されています。治療アドヒアランスや遠隔モニタリングと連動した月経追跡アプリのようなデジタルヘルスツールの統合は、治療成績とコンプライアンスをさらに向上させています。

市場の需要が加速している地域と主な利害関係者は？

北米が婦人科治療薬市場を独占しているが、これは主に強固なヘルスケア・インフラ、高い診断率、主要な医薬品イノベーターの存在によるものです。欧州がこれに続くが、欧米諸国の旺盛な需要は、国家的な医療プログラムや女性特有のケアへの取り組みの高まりに支えられています。アジア太平洋では、インド、中国、日本などの市場が、都市化、中間層のヘルスケアへのアクセスの増加、妊産婦とリプロダクティブ・ヘルスへの関心の高まりに後押しされ、需要の増加を目の当たりにしています。製薬会社、婦人科医、開業医、女性の健康擁護団体はすべて、この拡大する市場の主要利害関係者です。さらに、遠隔医療やオンライン薬局の台頭により、医薬品へのアクセスが向上し、十分な治療を受けられない地域における治療の障壁が低くなっています。

婦人科治療薬市場の成長を後押ししている要因は？

婦人科治療薬市場の成長は、女性の健康問題に対する意識の高まり、診断・治療施設へのアクセスの拡大、生殖やホルモンの状態に対する標的治療のポートフォリオの増加など、いくつかの要因によって牽引されています。ドラッグデリバリーシステムの技術的進歩、子宮筋腫や多嚢胞性卵巣症候群（PCOS）などの十分な治療を受けていない適応症に対する新規治療薬の導入、不妊治療に対する需要の高まりなどが市場をさらに活性化しています。さらに、婦人科がんに対する腫瘍学への医薬品研究開発投資、ホルモン療法や避妊に対する有利な規制支援や保険適用が、市場の持続的拡大に寄与しています。このようなダイナミクスにより、婦人科治療薬はより広範な製薬業界の中で重要な成長セグメントへと変貌しつつあります。

セグメント

治療薬（非ホルモン療法、ホルモン療法）、適応症（避妊適応症、女性不妊適応症、閉経後障害適応症、多嚢胞性卵巣症候群適応症、骨粗鬆症適応症、子宮内膜症適応症、その他の適応症）、流通チャネル（小売薬局、病院薬局、オンライン流通チャネル）

調査対象企業の例（注目の44社）

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Besins Healthcare
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cipla Limited
• Eli Lilly and Company
• Emcure Pharmaceuticals
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Gedeon Richter Plc
• Hetero Labs Limited
• Johnson & Johnson
• Lupin Pharmaceuticals Inc.
• Merck & Co., Inc.
• Novartis AG
• Organon & Co.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gynecology Drugs Market to Reach US$8.1 Billion by 2030

The global market for Gynecology Drugs estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.2% CAGR

The Gynecology Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global "Gynecology Drugs" Market - Key Trends & Drivers Summarized

Why Are Gynecology Drugs Becoming Central to Women’s Health Management?

Gynecology drugs are a fundamental part of the healthcare landscape, addressing a broad spectrum of conditions specific to women’s reproductive health-from menstrual disorders, hormonal imbalances, and endometriosis to infertility, menopause symptoms, and gynecological infections. As awareness surrounding women’s health issues continues to grow globally, more patients are actively seeking medical intervention for concerns that were previously stigmatized or undertreated. This cultural shift, along with increasing healthcare access, is driving demand for targeted pharmaceutical solutions. The expansion of gynecology-focused clinics and integration of women’s health into primary care pathways are contributing to earlier diagnosis and more consistent treatment across age groups and geographies.

How Is Innovation Reshaping Therapeutic Options for Gynecological Conditions?

The gynecology drugs market is evolving rapidly with the development of more effective, better-tolerated, and personalized therapeutic options. Hormone replacement therapies (HRT), selective estrogen receptor modulators (SERMs), and oral contraceptives are being reformulated with improved safety profiles and convenience-focused delivery methods, such as extended-release tablets, vaginal rings, and injectables. Non-hormonal drugs for conditions like menopause and endometriosis are gaining popularity among women seeking alternatives due to side effect concerns. Meanwhile, targeted biologics and immunotherapies are being explored for gynecologic cancers and chronic pelvic inflammatory diseases. The integration of digital health tools-like menstrual tracking apps linked to treatment adherence and remote monitoring-is further improving care outcomes and compliance.

Where Is Market Demand Accelerating and Who Are the Key Stakeholders?

North America dominates the gynecology drugs market, largely due to robust healthcare infrastructure, high diagnostic rates, and the presence of major pharmaceutical innovators. Europe follows closely, with strong demand in Western nations supported by national health programs and a rising focus on women-specific care initiatives. In Asia-Pacific, markets such as India, China, and Japan are witnessing increasing demand, fueled by urbanization, growing middle-class access to healthcare, and greater attention to maternal and reproductive health. Pharmaceutical companies, gynecologists, general practitioners, and women’s health advocacy groups are all key stakeholders in this expanding market. Additionally, the rise of telemedicine and online pharmacies is improving drug accessibility and reducing barriers to treatment in underserved regions.

What Factors Are Powering the Growth of the Gynecology Drugs Market?

The growth in the gynecology drugs market is driven by several factors, including increased awareness of women’s health issues, expanded access to diagnostic and treatment facilities, and a growing portfolio of targeted therapies for reproductive and hormonal conditions. Technological advances in drug delivery systems, the introduction of novel therapeutics for underserved indications such as uterine fibroids and polycystic ovary syndrome (PCOS), and rising demand for fertility treatments are further fueling the market. Additionally, pharmaceutical R&D investments in oncology for gynecological cancers, along with favorable regulatory support and insurance coverage for hormonal therapies and birth control, are contributing to sustained market expansion. These dynamics are transforming gynecology drugs into a key growth segment within the broader pharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Gynecology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (Non-Hormonal Therapy, Hormonal Therapy); Indication (Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication, Other Indications); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Besins Healthcare
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cipla Limited
• Eli Lilly and Company
• Emcure Pharmaceuticals
• Ferring Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Gedeon Richter Plc
• Hetero Labs Limited
• Johnson & Johnson
• Lupin Pharmaceuticals Inc.
• Merck & Co., Inc.
• Novartis AG
• Organon & Co.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Gynecology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of PCOS, Endometriosis, and Hormonal Disorders Drives Demand for Specialized Gynecology Drugs
  • Advances in Reproductive Health Treatments Strengthen Business Case for Targeted Gynecology Therapies
  • Increased Awareness of Womens Health Throws Spotlight on Early Diagnosis and Treatment Uptake
  • Expanding Access to Fertility Treatments and IVF Fuels Demand for Hormonal and Ovulation-Stimulating Drugs
  • Government and NGO-Led Awareness Campaigns Sustain Growth in Contraceptive and Preventive Therapies
  • Innovation in Hormone Replacement and Menopause Management Drives Market Differentiation
  • Regulatory Approvals and Pipeline Growth in Rare Gynecologic Conditions Expand Therapeutic Scope
  • Rise of Telehealth in Womens Health Enhances Accessibility to Prescription and OTC Treatments
  • Shift Toward Personalized Medicine in Gynecology Accelerates Use of Genomic and Targeted Drugs
  • Increased Investment in Endometriosis and Uterine Fibroid Research Propels Product Innovation
  • Consumer Demand for Non-Invasive and Oral Alternatives Supports Development of Novel Formulations
  • Integration of Gynecology Drug Portfolios by Big Pharma Strengthens Global Distribution Reach
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gynecology Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gynecology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Non-Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Non-Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Non-Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Contraception Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Contraception Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Contraception Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Female Infertility Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Female Infertility Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Female Infertility Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Postmenopausal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Postmenopausal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Postmenopausal Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Polycystic Ovary Syndrome Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Polycystic Ovary Syndrome Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Polycystic Ovary Syndrome Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Osteoporosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Osteoporosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Osteoporosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Endometriosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Endometriosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Endometriosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• JAPAN
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• CHINA
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• EUROPE
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Gynecology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• FRANCE
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• GERMANY
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Gynecology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• INDIA
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Gynecology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Gynecology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Gynecology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030
• AFRICA
  • Gynecology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Gynecology Drugs by Therapeutics - Non-Hormonal Therapy and Hormonal Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Gynecology Drugs by Therapeutics - Percentage Breakdown of Value Sales for Non-Hormonal Therapy and Hormonal Therapy for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Gynecology Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Gynecology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Gynecology Drugs by Indication - Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Gynecology Drugs by Indication - Percentage Breakdown of Value Sales for Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication and Other Indications for the Years 2014, 2025 & 2030

IV. COMPETITION